Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Lung Cancer”

1,391 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,391 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902
What this trial is testing

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 104
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Study completedNCT00043823
What this trial is testing

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 41
Not applicableStudy completedNCT02043002
What this trial is testing

Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)

Who this might be right for
Non-small Cell Lung Cancer Patients
University of Aarhus 67
Testing effectiveness (Phase 2)Study completedNCT01922583
What this trial is testing

AUY922 in Patient With Stage IV NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
National Taiwan University Hospital 31
Testing effectiveness (Phase 2)Looking for participantsNCT06864624
What this trial is testing

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Who this might be right for
NSCLC
Tang-Du Hospital 27
Testing effectiveness (Phase 2)UnknownNCT05430802
What this trial is testing

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Who this might be right for
Non-small Cell Lung Cancer
Tang-Du Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06962865
What this trial is testing

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 80
Early research (Phase 1)Looking for participantsNCT04762199
What this trial is testing

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more
Emory University 69
Early research (Phase 1)UnknownNCT03808701
What this trial is testing

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

Who this might be right for
Advanced Squamous Non-small Cell Lung Cancer
Sinocelltech Ltd. 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03433469
What this trial is testing

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Who this might be right for
Stage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung Cancer+4 more
University of California, San Francisco 27
Not applicableUnknownNCT00815971
What this trial is testing

Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib

Who this might be right for
Non-Small Cell Lung Cancer
Aarhus University Hospital 300
Large-scale testing (Phase 3)Study completedNCT03515837
What this trial is testing

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 492
Large-scale testing (Phase 3)Looking for participantsNCT06956001
What this trial is testing

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Who this might be right for
EGFRNSCLC (Advanced Non-small Cell Lung Cancer)
Allist Pharmaceuticals, Inc. 300
Not applicableStudy completedNCT02847377
What this trial is testing

A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Centre Georges Francois Leclerc 20
Not applicableWithdrawnNCT03519958
What this trial is testing

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca
Not applicableStudy completedNCT03309462
What this trial is testing

Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy

Who this might be right for
Lung Cancer
Shanghai Chest Hospital 50
Early research (Phase 1)Ended earlyNCT03255083
What this trial is testing

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 13
Testing effectiveness (Phase 2)Study completedNCT02183883
What this trial is testing

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Who this might be right for
Non-small Cell Lung Cancer
University College, London 12
Early research (Phase 1)Ended earlyNCT03246854
What this trial is testing

DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

Who this might be right for
Head and Neck CancerNSCLC
National Health Research Institutes, Taiwan 6
Load More Results